$VRTX

Generating a unique summary for VRTX…

AI-generated for information only — not investment advice.

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Institutions hold 98.31% · insiders 0.21% · 2,454 institutions

Consensus score 1.66 (1 = strong buy, 5 = sell) · mean target 571.46

• RBC CapitalOutperformmain2026-10-08
• UBSBuymain2026-09-28
• Truist SecuritiesBuymain2026-08-05
• BarclaysOverweightmain2026-08-05
• TD CowenBuymain2026-08-04
• Cantor FitzgeraldOverweightmain2026-08-04
• Canaccord GenuityHoldmain2026-08-04
• UBSBuymain2026-07-13
• Truist SecuritiesBuymain2026-07-13
• RBC CapitalOutperformmain2026-07-07

Next report: 2026-11-02

• 8-KCorporate Changes & Voting Matters2026-10-20Open
• 8-KCorporate Changes & Voting Matters2026-09-01Open
• 10-QPeriodic Financial Reports2026-08-04Open
• 8-KCorporate Changes & Voting Matters2026-08-03Open
• 8-KCorporate Changes & Voting Matters2026-07-07Open
• S-8 POSOffering Registrations2026-05-13Open
• 10-QPeriodic Financial Reports2026-05-05Open
• 8-KCorporate Changes & Voting Matters2026-05-04Open
• DEFA14AProxy Statements2026-04-29Open
• DEF 14AProxy Statements2026-04-02Open

• Vertex Pharmaceuticals (VRTX) Posts Positive Phase 3 Results For Povetacicept

  Vertex Pharmaceuticals (NasdaqGS:VRTX) reported positive Phase 3 results for povetacicept in IgA nephropathy, meeting all key endpoints. The late stage data are set to be published in the New England Journal of Medicine, highlighting the kidney disease program. Vertex plans to pursue FDA accelerated approval for povetacicept in IgA nephropathy following the Phase 3 readout. The successful povetacicept Phase 3 outcome in IgA nephropathy fits into a wider picture that recent research brings...

  Sun, 25 Oct 2026 03:19:56 +0000

• Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change.

  Vertex is expanding beyond its cystic fibrosis franchise.

  Sat, 24 Oct 2026 19:29:00 +0000

• Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III

  Vertex Pharmaceuticals (NASDAQ:VRTX) outlined updates across its kidney disease pipeline at the American Society of Nephrology Kidney Week 2026, highlighting data for povetacicept in IgA nephropathy and inaxaplin in APOL1-mediated kidney disease, or AMKD. Chief Executive Officer and President Reshm

  Sat, 24 Oct 2026 03:02:03 +0000

• Vertex Stock Looks Expensive. Does It Get Cheaper Ahead?

  For questions about this article or underlying research, email help@trefis.com.

  Fri, 23 Oct 2026 17:29:25 +0000

• Vertex Pharmaceuticals’ New Drugs Are Gaining Ground. Is That Enough for Investors?

  Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has spent years building a highly profitable cystic fibrosis franchise. Now, with newer treatments entering the market and its acquisition of Crinetics Pharmaceuticals completed, the company is working to establish additional sources of growth. The stock closed at $510.08 on October 9, with a forward P/E of 24.10, according to the […]

  Wed, 21 Oct 2026 15:19:02 +0000

• Why Should You Think About Vertex Differently Now?

  Vertex Pharmaceuticals (VRTX) stock trades at 28.9 times earnings, compared with 22.9 for the S&P 500, a price at which buyers appear to expect its growth to last. Before paying that price, you want to know what you own, and the company's priorities have changed. During its fiscal Q3 2024 call, management said it expected sustained revenue growth in cystic fibrosis (CF) over the short, medium and long term. The latest call still called CF a franchise with sustained growth, but it spent more time

  Wed, 21 Oct 2026 00:56:12 +0000

• AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

  AbbVie generates $17.8 billion in annual free cash flow but faces patent cliffs, while Vertex boasts a 33% net margin with concentrated cystic fibrosis exposure.

  Tue, 20 Oct 2026 21:35:02 +0000

• Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know

  Vertex Pharmaceuticals (VRTX) closed at $514.7 in the latest trading session, marking a +2.54% move from the prior day.

  Tue, 20 Oct 2026 20:50:03 +0000